TG Therapeutics (TGTX)
(Delayed Data from NSDQ)
$22.52 USD
+1.25 (5.88%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $22.54 +0.02 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Brokerage Reports
0 items in cart
TG Therapeutics, Inc. [TGTX]
Reports for Purchase
Showing records 81 - 100 ( 277 total )
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Positive Data in Follicular Lymphoma Cohort of UNITY-NHL
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Updated Phase 2 Extension Data for Ublituximab at ECTRIMS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
2Q19 Results; Important Milestones in 4Q19 and Early 2020
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Positive Updated Data Presented at ICML in Lugano
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Successful UNITY-NHL MZL Breakthrough Therapy Designation Meeting with FDA
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Company: TG Therapeutics, Inc.
Industry: Medical - Products
1Q19 Results; First FDA Submission Late 2019 or Early 2020
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Orphan Drug Designations Received for Three Marginal Zone Lymphoma Indications
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Umbralisib MZL Data at AACR Better Than Expected
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
TG Therapeutics Reports 4Q18 Results; Model Update, Positive DSMB Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
UNITY Delivers: Positive Outcome Reported in Phase 2b UNITY-NHL Pivotal Trial in MZL Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Takeaways From Management Meetings With Investors; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
TG Therapeutics Announces FDA Breakthrough Therapy Designation for Umbralisib in Treatment of MZL Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
TG Therapeutics and Dana-Farber Announce Phase 1/1B Umbralisib + Ibrutinib Combo Data Publication in Lancet Haematology
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
TG Therapeutics Presents Positive U2 Combination Data at ASH 2018
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
TG Therapeutics Opens Phase 1 TG-1701 Enrollment in R/R B-Cell Malignancies; U2 Updates Expected at ASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
TG Therapeutics 3Q18 Results; Awaiting Ublituximab and Umbralisib Data in 2019; PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
TG Therapeutics to Present Updated Umbralisib and Ublituximab Data at ASH 2018
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
TG Therapeutics Presents Final Phase 2 Ublituximab Data in MS at ECTRIMS; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E